心血管病生物靶向治疗的新时代到来

廖玉华; 邱志华; 陈霄

doi:10.13201/j.issn.1001-1439.2016.01.001

心血管病生物靶向治疗的新时代到来

- 华中科技大学同济医学院心血管病研究所、附属协和医院心内科、教育部生物靶向治疗研究重点实验室(武汉, 430022)

详细信息

通讯作者: 廖玉华,E-mail:liaoyh27@163.com

中图分类号: R541

收稿日期: 2015-12-01

The advent of a new era of biological target therapy for cardiovascular diseases

- Key Laboratory of Biological Targeted Therapy of the Ministry of Education, Institute of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Corresponding author: LIAO Yuhua, E-mail: liaoyh27@163.com

Received Date: 01 December 2015

摘要

摘要: 慢性心血管病严重危害人类健康,治疗现状不容乐观。生物靶向治疗技术如抗体、疫苗、基因、干细胞等靶向性强、作用时间长且治疗效应平稳,对于改变慢性心血管病的治疗现状,降低其患病率和病死率具有重要意义。随着PCSK9单抗的成功上市,心血管病生物靶向治疗的新时代已然到来。
- 心血管病 /
- 生物靶向治疗 /
- 单克隆抗体 /
- 疫苗 /
- 基因治疗 /
- 干细胞治疗
Abstract: Chronic cardiovascular diseases constitute a serious hazard to human health, and the present status of treatment is not optimistic. Biological target therapeutic techniques (antibodies, vaccines, gene, stem cell), possess several advantages as compared with other drugs, such as long-acting time, strong targeting ability and smooth effect. Biological target therapeutic techniques can significantly improve current treatment status, and reduce the morbidity and mortality of chronic cardiovascular diseases. The PCSK9 monoclonal antibodies had been approved into the market, indicating the advent of a new era of biological target therapy for cardiovascular diseases.
- cardiovascular diseases /
- biological target therapy /
- monoclonal antibody /
- vaccine /
- gene therapy /
- stem cell therapy

HTML全文

参考文献(17)

[1]	DADU R T,BALLANTYNE C M.Lipid lowering with PCSK9inhibitors[J].Nat Rev Cardiol,2014,11:563-575.
[2]	FITZGERALD K,FRANK K M,SHULGA M S,et al.Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9(PCSK9)and the concentration of serum LDL cholesterol in healthy volunteers:a randomised,singleblind,placebo-controlled,phase 1trial[J].Lancet,2014,383:60-68.
[3]	CROSSEY E,AMAR M,SAMPSON M,et al.A cholesterol-lowering VLP vaccine that targets PCSK9[J].Vaccine,2015,33:5747-5755.
[4]	MARC S S,ROBERT P G,STEPHEN D W,et al.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J].The New England Journal of Medicine,2015,372:1500-1509.
[5]	JENNIFER G R,MICHEL F,MICHEL K,et al.Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J].The New England Journal of Medicine,2015,372:1489-1499.
[6]	TISSOT A C,MAURER P,NUSSBERGER J,et al.Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure:a double-blind,randomised,placebo-controlled phase IIa study[J].Lancet,2008,371:821-827.
[7]	NAKAGAMI F,KORIYAMA H,NAKAGAMI H,et al.Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice[J].PLoS One,2013,8:e60493.
[8]	OU X,GUO L,WU J,et al.Construction,expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle[J].Hum Vaccin Immunother,2013,9:1191-1199.
[9]	KORIYAMA H,NAKAGAMI H,NAKAGAMI F,et al.Long-term reduction of high blood pressure by angiotensin II DNA vaccine in spontaneously hypertensive rats[J].Hypertension,2015,66:167-174.
[10]	LI LD,TIAN M,LIAO YH,et al.Effect of active immunization against angiotensin II type 1(AT1)receptor onhypertension&arterial remodelling in spontaneously hypertensive rats(SHR)[J].Indian J Med Res,2014,139:619-624.
[11]	CHEN X,QIU ZH,YANG SJ,et al.Effectiveness and safety of a therapeutic vaccine against at1receptor in hypertensive animals[J].Hypertension,2013,61:408-416.
[12]	DING D,DU Y,QIU Z,et al.Vaccination against type 1angiotensin receptor prevents streptozotocin-induced diabetic nephropathy[J].J Mol Med(Berl),2015,Sep 26.DOI 10.1007/s00109-015-1343-6.
[13]	ZSEBO K,YAROSHINSKY A,RUDY J,et al.Long-term effects of AAV1/SERCA2agene transfer in patients with severe heart failure:analysis of recurrent cardiovascular events and mortality[J].Circ Res,2014,114:101-108.
[14]	WAHQUIST C,JEONG D,ROJAS M A,et al.Inhibition of miR-25improves cardiac contractility in the failing heart[J].Nature,2014,508:531-535.
[15]	CELLADON.Celladon reports negative results for CUPID2trial of MYDICAR in advanced heart failure.Press release,26April 2015.
[16]	PATEL A N,MITTAL S,TURAN G,et al.REVIVE Trial:Retrograde Delivery of Autologous Bone Marrow in Patients With Heart Failure[J].Stem Cells Transl Med,2015,4:1021-1027.
[17]	PERIN E C,BOROW K M,SILVA G V,et al.A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure[J].Circ Res,2015,117:576-584.